Management of secondary progressive multiple sclerosis: prophylactic treatment-past, present, and future aspects (Q38101003)

28 August 2017

Management of secondary progressive multiple sclerosis: prophylactic treatment-past, present, and future aspects (English)

1 reference

secondary progressive multiple sclerosis

28 August 2017

0 references

0 references

2

Olaf Stüve

1 reference

28 August 2017

Paulus S Rommer

1

1 reference

PubMed ID

23609781

28 August 2017

language of work or name

1 reference

1 June 2013

1 reference

Current treatment options in neurology

28 August 2017

1 reference

28 August 2017

15

1 reference

28 August 2017

3

1 reference

28 August 2017

241-258

1 reference

https://scigraph.springernature.com/pub.10.1007/s11940-013-0233-x

28 August 2017

0 references

cites work

Defining the clinical course of multiple sclerosis: Results of an international survey

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

The relation between inflammation and neurodegeneration in multiple sclerosis brains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Neurodegeneration in multiple sclerosis: novel treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Cortical lesions in multiple sclerosis: inflammation versus neurodegeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

A critical appraisal of treatment decisions in multiple sclerosis--old versus new.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Costs and quality of life of patients with multiple sclerosis in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Suppression of demyelination by mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

An open-trial evaluation of mitoxantrone in the treatment of progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Overview of azathioprine treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Use of intravenous immunoglobulin in the treatment of immune-mediated demyelinating diseases of the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Mycophenolate mofetil in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: are we close to reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Cladribine in treatment of chronic progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

The treatment of chronic progressive multiple sclerosis with cladribine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Whole brain volume changes in patients with progressive MS treated with cladribine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

The effect of cladribine on T(1) 'black hole' changes in progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Placebo-controlled trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0233-X

Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease

21 January 2018

1 reference

12 December 2020

Follow-up study of MS patients treated with high-dose intravenous methylprednisolone

1 reference

12 December 2020

A double blind study on azathioprine efficacy in multiple sclerosis: final report

1 reference

12 December 2020

The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group

1 reference

12 December 2020

Progressive multiple sclerosis: pathology and pathogenesis

1 reference

12 December 2020

Treatment of active secondary progressive multiple sclerosis with treosulfan

1 reference

12 December 2020

A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis

1 reference

12 December 2020

Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study

1 reference

12 December 2020

Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study

1 reference

12 December 2020

Rituximab for secondary progressive multiple sclerosis: a case series

1 reference

12 December 2020

Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials

1 reference

12 December 2020

Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis.

1 reference

12 December 2020

Evaluating the potential benefit of interferon treatment in multiple sclerosis

1 reference

12 December 2020

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

12 December 2020

Noninvasive Assessment of Mitoxantrone Cardiotoxicity in Relapsing Remitting Multiple Sclerosis

1 reference

12 December 2020

Immunomodulation of autoimmunity by linomide: inhibition of antigen presentation through down regulation of macrophage activity in the model of experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators

1 reference

12 December 2020

The natural history of multiple sclerosis: update 1998

1 reference

12 December 2020

Linomide downregulates autoimmunity through induction of TH2 cytokine production by lymphocytes

1 reference

12 December 2020

Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis

1 reference

12 December 2020

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

12 December 2020

Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody

1 reference

12 December 2020

Cyclophosphamide Treatment of MS: Current Therapeutic Approaches and Treatment Regimens

1 reference

12 December 2020

MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS)

1 reference

12 December 2020

Determination of cyclophosphamide in urine, serum and cerebrospinal fluid of multiple sclerosis patients by field desorption mass spectrometry

1 reference

12 December 2020

Cyclosporine versus azathioprine in the treatment of multiple sclerosis: 12-month clinical and immunological evaluation

1 reference

12 December 2020

Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation

1 reference

12 December 2020

High-dose methylprednisolone infusions in relapsing and in chronic progressive multiple sclerosis patients. One year follow-up

1 reference

12 December 2020

Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials

1 reference

12 December 2020

Control of immune-mediated disease of the central nervous system with monoclonal (CD4-specific) antibodies

1 reference

12 December 2020

10.1007/S11940-013-0233-X

Identifiers

DOI

1 reference

28 August 2017

1 reference

PubMed ID

23609781